AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance

February 3, 2021 7:39 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.92, $0.06 better than the analyst estimate of $2.86. Revenue for the quarter came in at $13.86 billion versus the consensus estimate of $13.73 billion.


AbbVie sees FY2021 EPS of $12.32-$12.52, versus the consensus of $12.18.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities